Asymmetrex Awarded Grant from ARMI BioFabUSA to Develop Tissue Stem Cell Counting Technology for Cell Biomanufacturing

Asymmetrex Awarded Grant from ARMI BioFabUSA to Develop Tissue Stem Cell Counting Technology for Cell Biomanufacturing

Stem cell biotechnology company Asymmetrex has been awarded a Technical Project grant from Advanced Regenerative Manufacturing Institute (ARMI) BioFabUSA. The new grant supports studies by Asymmetrex to evaluate its kinetic stem cell (KSC) counting technology as a method for determining a long-needed critical quality attribute for the biomanufacturing of potent therapeutic tissue stem cell-based products.

Asymmetrex Plans to Review Tissue Stem Cell Reports that Need Stem Cell Counting

Asymmetrex Plans to Review Tissue Stem Cell Reports That Need Stem Cell Counting

James L. Sherley, M.D., Ph.D., President and CEO of stem cell biotechnology Asymmetrex, says that it is time for his company to take a more active role in providing information on the opportunities missed when the stem cell medicine industry continues to treat patients without knowing the dosage of the stem cells. On September 8,

Asymmetrex Interviewed by SuperbCrew About New Web Portal With Tools for Therapeutic Stem Cell Applications

Asymmetrex Interviewed by SuperbCrew About New Web Portal With Tools for Therapeutic Stem Cell Applications

Last week on June 21 with the start of its participation in the virtual 2021 Annual Meeting of the International Society for Stem Cell Research, stem cell biotechnology company Asymmetrex launched a new web portal that provides scientists free online access to calculators for important parameters used in human tissue cell research.  In a June 30 post, business and technology news platform SuperbCrew interviewed Asymmetrex’s

Asymmetrex-Provides-Scientists-At-ISSCR-2021-Access-To-A-Missing-Critical-Quality-Attribute-For-Stem-Cell-Research-and-Medicine

Asymmetrex Provides Scientists At ISSCR 2021 Access To A Missing Critical Quality Attribute For Stem Cell Research and Medicine

Yesterday, June 23, stem cell biotechnology company Asymmetrex presented its latest advances in stem cell technology to attendees in the 2021 Annual Meeting of the International Society for Stem Cell Research, which runs from June 21-26.  The research presentation (Poster #345) highlighted applications in stem cell research and medicine for the company’s first-in-kind technology for quantifying therapeutic

Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting

Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting

Next week, June 21-26, stem cell biotechnology company Asymmetrex will participate as a presenter and an exhibitor in the 2021 Annual Meeting of the International Society for Stem Cell Research.  In an invited poster presentation (#345) and a company exhibitor display, Asymmetrex will introduce the virtual gathering of international stem cell scientists, physicians, and biotechnologists to

Asymmetrex Interviewed by SuperbCrew About Upcoming Presentations at ISSCR 2021

Asymmetrex Interviewed by SuperbCrew About Upcoming Presentations at ISSCR 2021

In a June 11 posting, online business and technology news portal SuperbCrew reported their recent interview with Asymmetrex President and CEO James L. Sherley, M.D., Ph.D. about the company’s upcoming first participation in an annual meeting of the International Society for Stem Cell Research. Asymmetrex’s exhibitor display and research poster #345 presentation in the virtual

Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies New

Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies

Today, May 20, in the virtual 5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., introduced company executives and scientists to new technologies for determining the dosage of therapeutic stem cell products and treatments. A Gold Sponsor for the conference, Asymmetrex’s kinetic

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells

During the coming months of May and June, stem cell biotechnology company Asymmetrex is invited to give presentations in several different virtual conferences that span the fields of clinical trial supply, cell biotherapeutics, stem cell science, and stem cell medicine. The company’s relevance to these diverse disciplines reflects the broad scope of the impact of

Asymmetrex Describes How New Technologies for Quantifying Stem Cell Dosage Will Improve the Effectiveness of the Stem Cell Clinical Trial Supply Chain

Asymmetrex Describes How New Technologies for Quantifying Stem Cell Dosage Will Improve the Effectiveness of the Stem Cell Clinical Trial Supply Chain

On March 24, in Arena International’s 2021 Virtual Conference on Clinical Trial Supply-Europe, stem cell biotechnology company Asymmetrex described emerging technologies that will end a critical knowledge gap in the supply chain for stem cell clinical trials. Asymmetrex CEO, James L. Sherley, discussed how the effectiveness of the supply chain will improve with the introduction